Cargando…
Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies
Small-cell lung cancer (SCLC) is an aggressive disease with distinct biological and clinical features. The clinical course of SCLC is generally characterised by initial sensitivity to DNA-damaging therapies, followed by early relapse and broad cross resistance to second line agents. Whilst there has...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179261/ https://www.ncbi.nlm.nih.gov/pubmed/37175833 http://dx.doi.org/10.3390/ijms24098129 |